Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation

In a US database study of obese adults with type 2 diabetes and rheumatoid arthritis, starting semaglutide was associated with fewer major cardiovascular events than starting other glucose-lowering drugs, mainly due to fewer heart failure cases. The analysis emulated a randomized target trial using propensity-matched groups, but was observational.

Journal article — target-trial emulation, retrospective observational database study. Population: Obese adults (BMI ≥30 kg/m²) with type 2 diabetes and comorbid rheumatoid arthritis, no prior stroke, heart failure, acute coronary syndrome, or coronary revascularization, from the TriNetX US database. Sample size: 1017 semaglutide users and 1017 non-GLP-1RA users after propensity-score matching. Follow-up: follow-up of up to 2 years. Interventions: Semaglutide.

Semaglutide initiation was associated with a significantly lower risk of incident MACCE compared with non-GLP-1RA therapies (12.7% vs. 16.5%; HR, 0.75; 95% CI, 0.60-0.94; P = 0.01). This benefit was driven primarily by a lower risk of incident heart failure (8.9% vs. 12.5%; HR, 0.69; 95% CI, 0.53-0.91; P = 0.007). Semaglutide use was also associated with significantly lower DMARD escalation (16.6% vs. 21.6%; HR, 0.75; 95% CI, 0.60-0.90; P = 0.003). No significant differences were observed in all-cause mortality, myocardial infarction, or stroke.

This paper provides real-world evidence on semaglutide's potential cardiovascular benefits in a high-risk subgroup—obese patients with type 2 diabetes and rheumatoid arthritis—that is often underrepresented in cardiovascular outcome trials. It does not establish causality, provide dosing information, or clarify mechanisms, and requires confirmation in prospective studies.

Key findings

• Semaglutide initiation was associated with a significantly lower risk of incident MACCE compared with non-GLP-1RA therapies (12.7% vs. 16.5%; HR, 0.75; 95% CI, 0.60-0.94; P = 0.01).
• The reduced MACCE risk was driven primarily by a lower risk of incident heart failure (8.9% vs. 12.5%; HR, 0.69; 95% CI, 0.53-0.91; P = 0.007).
• Semaglutide use was associated with significantly lower DMARD escalation (16.6% vs. 21.6%; HR, 0.75; 95% CI, 0.60-0.90; P = 0.003).
• No significant differences were observed in all-cause mortality, myocardial infarction, or stroke.

Limitations

• Observational design cannot establish causality, as the authors note and call for prospective studies.
• Target-trial emulation is subject to residual confounding despite propensity-score matching.
• Single US database (TriNetX) may limit generalizability.
• Follow-up was limited to up to 2 years.

The record

• Journal: European heart journal. Cardiovascular pharmacotherapy 12(5): 368-378
• Published: 2026-08-17
• PMID: 42334436 — DOI: 10.1093/ehjcvp/pvag044
• MeSH terms: Humans, Arthritis, Rheumatoid, Cerebrovascular Disorders, Diabetes Mellitus, Type 2, Obesity, Hypoglycemic Agents, Treatment Outcome, Incidence, Risk Assessment, Risk Factors, Comorbidity, Primary Prevention, Time Factors, Databases, Factual, Aged, Middle Aged, United States, Female, Male, Glucagon-Like Peptides, Incretins, Semaglutide
• Author countries: Taiwan, USA

Peptide profiles: Semaglutide.

All indexed evidence: Semaglutide trials & papers.

Related studies: Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia…, Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults…, Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and…, Effect of tirzepatide and semaglutide on blood pressure: A systematic review and….